Shanghai Pharma Reports 2025 Interim Results: 1.6% Revenue Rise, 41% Profit Surge
Shanghai Pharmaceutical Holding Co., Ltd. (SHA: 601607, HKG: 2607) on Aug. 28, 2025 announced its...
Zennova & Rapafusyn Forge BioCarier‑Powered RapaGlue Collaboration – 2025
Zennova Pharmaceuticals Group and Rapafusyn Pharmaceuticals on Aug. 28, 2025 announced a strategic collaboration to...
Boehringer Ingelheim & Sino Biopharma Secure Conditional Approval for Zongertinib in China
In a joint announcement, Boehringer Ingelheim (BI) and Sino Biopharmaceutical Limited (HKG: 1177) confirmed that the...
Innovent Biologics Revenue Soars 50% in H1 2025 – Oncology Growth Fuels GLP‑1 Expansion
China-based Innovent Biologics, Inc. (HKG: 1801) on Aug. 28, 2025 released its semi‑annual financial results for...
NHSA 2025 Drug Catalog Review: 6 Drugs Rejected, 718 Applications Reviewed
The National Healthcare Security Administration (NHSA) on Aug. 28, 2025 announced the formal review outcomes...
HarbourBioMed Reports 327 % Revenue Surge, Launches HCAb‑Based Élancé Therapeutics
Harbour BioMed (HKG: 2142) on Aug. 27, 20025 released its first‑half 2025 financial results, reporting...
Santen Receives Boao Lecheng Approval for RYJUSEA – A Preservative‑Free Atropine Eye Drop for Pediatric Myopia
Japan‑based Santen Pharmaceutical Co., Ltd. (TYO: 4536) announced that its RYJUSEA (atropine sulfate hydrate) has...
Anglikang Secures Exclusive Rights to Yafei’s IMD‑1005 in China
Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) announced that it has entered into a license...
RemeGen’s Telitacicept Hits Primary Endpoint in Phase III IgA Nephropathy Trial
China‑based RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) on Aug, 27, 2025announced that its first‑in‑class BLyS/APRIL...
ImmuneOnco Secures $5 M Milestone from Instil Bio, Strengthening Axion Bio Collaboration
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) on Aug 28, 2025 announced the receipt of...
Shandong Boan Biotechnology Reports 8% YoY Revenue Growth, 3‑Year Profit Trend
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd (HKG: 6955)...
HitGen’s 2025 H1 Report Shows 16.58% Revenue Growth and 391% Profit Surge
China-based HitGen Inc. (SHA: 688222) on Aug 27, 2025 released its semi‑annual financial results for...
Changchun High Files GenSci134 Clinical Trial for Growth Hormone Deficiency
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) on Aug 27, 2025 disclosed...
Fosun Pharma Grants Sitala Global License for FXS6837 – Up to $190 M Milestones
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) today announced a License Agreement...
Regeneron’s Cemdisiran Beats Key Milestones in Phase III gMG Trial
US-based Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Aug 27, 2025 disclosed that its investigational monotherapy, cemdisiran,...
Gilead’s Yeytuo Gains EU Marketing Authorization for Twice‑Yearly HIV‑1 PrEP
European Commission Grant – On 26 Aug 2025 Gilead Sciences (NASDAQ: GILD) announced that the European Commission...
TYK Medicines Secures Exclusive Distribution of TY‑9591 in Mainland China
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 26, 2025, that it has entered...
Fosun Pharma Reports 4.6% Revenue Decline in 2025 H1 – Innovative Drugs Drive Growth
China‑based Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) released its 2025 first‑half...
C‑MER Announces Acquisition of Hong Kong Endoscopy Centre
C‑MER Eye Care Medical Group Limited (HKG: 3309) on 26 August, 2025 disclosed plans to acquire a...
Junshi Biosciences Reports 49% Revenue Growth in H1 2025
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) released its interim financials for the...